Your Online Resource for BioProcess Technology
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Saturday, May 19, 2018  |  Volume 10 / Number 7  |  A Production of the BioProcessing Journal
The Waterside Conference
Career Development
Protein Chromatography Course – Engineering Fundamentals and Measurement for Process Development and Scale-Up
May 27–June 1, 2018
Vienna, Austria
MSS 2018
Monolith Chromatography Summer School and Symposium
June 15–20, 2018
Portorož, Slovenia
Cell & Gene Therapy Europe
Immuno-Oncology Frontiers Europe
September 10–12, 2018
London, United Kingdom
Cancer & Autoimmunity
September 17–21, 2018
Varadero, Cuba
July 29August 2, 2018
Washington, DC USA
XXVI Annual Congress
October 16–19, 2018
Lausanne, Switzerland
Suggested Reading
Integrating Development Tools into the Process Validation Lifecycle
to Achieve Six Sigma Pharmaceutical Quality
By Mark F. Witcher, PhD, NNE
Products & Services
First-Ever Chemically Defined Insect Protein Expression System

Focused on removing barriers to vaccine development and production, Thermo Fisher Scientific announced its Gibco ExpiSf system, the first-ever chemically defined insect protein expression system. The revolutionary ExpiSf system brings together the company’s Gibco media technology, Lipofectamine transfection technology, and molecular biology expertise to deliver three times more protein and consistent results. ExpiSf has been optimized for the generation of high-quality baculovirus using a suspension-based transfection protocol that delivers protein in half the time compared to traditional insect platforms. The superior performance enables customers to realize significant time savings without sacrificing quality and reproducibility across experiments.

For more information, please visit

Anti-Vedolizumab Antibodies

Bio-Rad Laboratories, Inc. has released a range of anti-vedolizumab antibodies. Vedolizumab (Entyvio) is a monoclonal antibody used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad’s anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanized IgG1 kappa antibody drug, vedolizumab.

Bio-Rad’s recombinant monoclonal anti-vedolizumab antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, results in highly targeted reagents. The paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. The recombinant production method ensures a consistent and secure supply.
anti-vedolizumab antibodies.
Bio-Rad’s anti-vedolizumab antibodies are approved for in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development and patient monitoring. For more information, please visit
Production and Purification of Large DNA Plasmids

BIA Separations and Biomay have announced a collaboration on the high-yield production of large DNA plasmids. The companies have co-developed an economical production system for double-digit gram-scale production and purification of plasmids larger than 20,000 base pairs (20 kbp) achieving high recovery of 95% supercoiled DNA. The new manufacturing process addresses a major challenge in the scaled manufacture of plasmid DNA and represents a significant step towards the wide application of large DNA plasmids in cell and gene therapy.

high-yield production of large DNA plasmids
The collaboration combines Biomay’s experience in the production of GMP-conform ultrapure pDNA with BIA Separations’ CIM® (Convective Interaction Media) monolithic chromatographic columns. Monoliths support effective purification for plasmids up to at least 60 kbp and are able to maintain high capacity and resolution at high flow rates regardless of the size of the molecules being separated.
The system is commercially available to clients through Biomay´s GMP service offerings. 

For more information, please visit
Job Opening
Senior Scientist - Analytical R&D, Gene Therapy
St. Louis, Missouri USA
Career Development
Cell & Gene Therapy Products
July 10–12, 2018
Rockville, Maryland USA
CMC Strategy Forum Summer
July 16–17, 2018
Gaithersburg, Maryland USA
Vaccine Technology VII
June 1722, 2018
Mont Tremblant, Quebec, Canada
PREP 2018—31st International Symposium on Preparative and Process Chromatography
July 8–11, 2018
Baltimore, Maryland USA
Cell Culture-Based Viral Vaccines Course – Third Edition
September 18–21, 2018
Animal Cell Technology Course 2018 – Eighth Edition
September 23–27, 2018
Llafranc, Costa Brava, Spain
Advertising: Request a media kit!
Banner description: Primary hepatocytes at 10x; DAPI, GFP and Texas Red.
Image captured with Cytation 5 Cell Imaging Multi-Mode Reader. Courtesy of BioTek.
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.